查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1581287

标靶治疗市场：按类型、作用机制、分销管道和治疗领域划分 - 全球预测 2025-2030

Targeted Therapy Market by Type (Monoclonal Antibodies, Small Molecule Medicines), Mechanism of Action (Angiogenesis Inhibitors, Apoptosis Inducers, Gene Expression Modulators), Distribution Channel, Therapeutic Area - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年标靶治疗市场估值为627.5亿美元，预计2024年将达671.6亿美元，复合年增长率为7.44%，到2030年将达到1037.5亿美元。

标靶治疗是一种创新的癌症治疗形式，它使用药物或其他物质来精确识别和攻击癌细胞，通常不会伤害正常细胞。这种方法需要深入了解癌症的分子和遗传基础，并针对参与肿瘤生长和进展的特定分子。应用包括多种癌症类型，并且越来越重视个人化医疗，根据个人的基因谱提供量身定制的治疗。最终使用领域包括医院肿瘤科、专业癌症治疗中心和研究机构。

主要市场统计
基准年[2023] 627.5亿美元
预测年份 [2024] 671.6亿美元
预测年份 [2030] 1037.5亿美元
复合年增长率（%） 7.44%

根据市场洞察，标靶治疗的成长受到癌症发病率上升、基因组技术进步以及精准医疗需求不断增长的显着影响。政府对癌症研究的支持进一步推动了这个市场。公司不断创新，旨在提高治疗的特异性和有效性，同时最大限度地减少副作用。最新的商机在于开发新型生物标记和伴同性诊断，以推动个人化治疗计划。为了利用这些机会，公司需要投资研发合作并扩大其药物管道组合。

然而，挑战依然存在，包括高昂的开发和治疗成本、监管障碍以及复杂的临床试验流程。此外，可能会对标靶治疗治疗产生抗药性，从而降低长期疗效。肿瘤遗传学的复杂性也为精确定位标靶带来了挑战，需要继续研究和完善现有的治疗方法。

创新和研究工作应着重于扩大现有疗法的适应症、探索协同联合治疗以及利用人工智慧进行药物发现。由于市场竞争激烈且充满活力，企业必须保持适应能力，强调持续创新和以市场为导向的研究以维持成长。简而言之，市场的本质要求敏捷性，企业需要快速适应技术进步和不断变化的消费者需求，以保持竞争力。

市场动态：揭示快速发展的标靶治疗市场的关键市场洞察

供给和需求的动态相互作用正在改变标靶治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球癌症易感性盛行率不断增加
    • 增加整个全部区域药物开发的投资
    • 改善癌症治疗的法律规范和指南
  • 市场限制因素
    • 治疗高成本
  • 市场机会
    • 日益关注个人化医疗的联合治疗
    • 使用次世代定序仪(NGS) 和 CRISPR 的基因分析技术的进步
  • 市场挑战
    • 患者对标靶治疗的反应存在差异

波特五力：开拓标靶治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解标靶治疗市场的外部影响

外部宏观环境因素在塑造标靶治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解标靶治疗市场的竞争格局

标标靶治疗市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的见解，以应对日益激烈的竞争。

FPNV定位矩阵标标靶治疗市场供应商绩效评估

FPNV定位矩阵是评估标靶治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製标靶治疗市场的成功之路

标靶治疗市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球癌症发生率上升
      • 各地区药物开发投资增加
      • 改善癌症治疗的法规结构和指南
    • 抑制因素
      • 治疗费用高
    • 机会
      • 日益关注个人化医疗的联合治疗
      • 用于基因结构分析的次世代定序(NGS) 和 CRISPR 技术进步
    • 任务
      • 患者对标靶治疗的反应存在差异
  • 市场区隔分析
    • 类型：扩大单株抗体在个人化医疗中的使用
    • 治疗领域：肺癌治疗快速推广，投资庞大
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章标靶治疗市场：依类型

  • 单株抗体
  • 小分子药物

第七章依作用机转分類的标靶治疗市场

  • 血管新生抑制剂
  • 细胞凋亡诱导剂
  • 基因表现因子
  • 荷尔蒙疗法
  • 讯号传导抑制剂

第八章标靶治疗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第九章按治疗领域标靶治疗市场

  • 乳癌
  • 大肠直肠癌
  • 白血病
  • 肺癌
  • 淋巴瘤
  • 多发性硬化症
  • 肾癌

第十章美洲标靶治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太标标靶治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲标靶治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 诺华收购 Mariana Oncology 加强癌症治疗手段
    • 德尔菲亚生物技术公司推出标靶和杀死癌细胞的创新方法
    • 诺华在印度推出治疗慢性骨髓性白血病的新药，为患者提供更好的治疗选择
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc.
  • Bristol Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche AG
  • Genmab A/S
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-CA7E340319CF

The Targeted Therapy Market was valued at USD 62.75 billion in 2023, expected to reach USD 67.16 billion in 2024, and is projected to grow at a CAGR of 7.44%, to USD 103.75 billion by 2030.

Targeted therapy is an innovative form of cancer treatment that uses drugs or other substances to precisely identify and attack cancer cells, usually without harming normal cells. This approach necessitates a deep understanding of the molecular and genetic bases of cancer, targeting specific molecules involved in tumor growth and progression. Applications range across various types of cancers, with a growing emphasis on personalized medicine, where treatments are tailored to individual genetic profiles. End-use sectors prominently include oncology departments in hospitals, specialized cancer treatment centers, and research institutions.

KEY MARKET STATISTICS
Base Year [2023] USD 62.75 billion
Estimated Year [2024] USD 67.16 billion
Forecast Year [2030] USD 103.75 billion
CAGR (%) 7.44%

Market insights reveal targeted therapy's growth is significantly influenced by rising cancer prevalence, advances in genomic technologies, and increasing demand for precision medicine. Government support for cancer research further bolsters this market. Companies are consistently innovating, aiming to improve the specificity and efficacy of treatments while minimizing side effects. The latest opportunities lie in the development of novel biomarkers and companion diagnostics, propelling personalized treatment plans. To capitalize on these opportunities, firms should invest in R&D collaborations and broaden their drug pipeline portfolios.

However, challenges persist, such as the high costs of development and treatment, regulatory hurdles, and complex clinical trial processes. Additionally, resistance to targeted therapies can develop, leading to reduced long-term efficacy. The intricacies of tumor genetics also pose challenges in accurately identifying targets, necessitating ongoing research and refinement of existing therapies.

Innovation and research efforts should focus on expanding indications for existing therapies, exploring synergistic combination treatments, and leveraging artificial intelligence for drug discovery. As the market is highly competitive and dynamic, businesses must remain adaptable, emphasizing continuous innovation and market-oriented research to sustain growth. In essence, the nature of the market demands agility, with companies needing to swiftly adapt to technological advancements and evolving consumer demands to maintain a competitive edge.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Targeted Therapy Market

The Targeted Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cancer susceptibility globally
    • Rising investment in drug development across geographies
    • Improved regulatory frameworks and guidelines for cancer treatment
  • Market Restraints
    • High cost associated with treatment
  • Market Opportunities
    • Increased focus on combination therapies for personalized medicine
    • Technological advancements in next-generation sequencing (NGS) and CRISPR for genetic makeup
  • Market Challenges
    • Variability in patient response to targeted therapies

Porter's Five Forces: A Strategic Tool for Navigating the Targeted Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Targeted Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Targeted Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Targeted Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Targeted Therapy Market

A detailed market share analysis in the Targeted Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Targeted Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Targeted Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Targeted Therapy Market

A strategic analysis of the Targeted Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Targeted Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BeiGene, Ltd., Biogen Inc., BioMarin Pharmaceutical Inc., Bristol Myers Squibb Company, Eisai Co., Ltd., Eli Lilly and Company, Exelixis, Inc., F. Hoffmann-La Roche AG, Genmab A/S, Gilead Sciences, Inc., GlaxoSmithKline plc, Incyte Corporation, Johnson & Johnson Services, Inc., Merck & Co., Inc., Merck KGaA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Targeted Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Monoclonal Antibodies and Small Molecule Medicines.
  • Based on Mechanism of Action, market is studied across Angiogenesis Inhibitors, Apoptosis Inducers, Gene Expression Modulators, Hormone Therapies, and Signal Transduction Inhibitors.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Therapeutic Area, market is studied across Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Sclerosis, and Renal Cancer.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer susceptibility globally
      • 5.1.1.2. Rising investment in drug development across geographies
      • 5.1.1.3. Improved regulatory frameworks and guidelines for cancer treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased focus on combination therapies for personalized medicine
      • 5.1.3.2. Technological advancements in next-generation sequencing (NGS) and CRISPR for genetic makeup
    • 5.1.4. Challenges
      • 5.1.4.1. Variability in patient response to targeted therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Expanding usage of monoclonal antibodies for personalized medicine
    • 5.2.2. Therapeutic Area: Rapid adoption of lung cancer therapies with substantial investment
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Targeted Therapy Market, by Type

  • 6.1. Introduction
  • 6.2. Monoclonal Antibodies
  • 6.3. Small Molecule Medicines

7. Targeted Therapy Market, by Mechanism of Action

  • 7.1. Introduction
  • 7.2. Angiogenesis Inhibitors
  • 7.3. Apoptosis Inducers
  • 7.4. Gene Expression Modulators
  • 7.5. Hormone Therapies
  • 7.6. Signal Transduction Inhibitors

8. Targeted Therapy Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Targeted Therapy Market, by Therapeutic Area

  • 9.1. Introduction
  • 9.2. Breast Cancer
  • 9.3. Colorectal Cancer
  • 9.4. Leukemia
  • 9.5. Lung Cancer
  • 9.6. Lymphoma
  • 9.7. Multiple Sclerosis
  • 9.8. Renal Cancer

10. Americas Targeted Therapy Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Targeted Therapy Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Targeted Therapy Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Novartis Strengthens Cancer Treatment Arsenal with Acquisition of Mariana Oncology
    • 13.3.2. Delphia Biotech Introduces Launched a Revolutionary Approach Targeting and Killing Cancer Cells
    • 13.3.3. Novartis to Launch New Chronic Myeloid Leukemia Drug in India, Offering Improved Treatment Options for Patients
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. Astellas Pharma Inc.
  • 4. AstraZeneca PLC
  • 5. Bayer AG
  • 6. BeiGene, Ltd.
  • 7. Biogen Inc.
  • 8. BioMarin Pharmaceutical Inc.
  • 9. Bristol Myers Squibb Company
  • 10. Eisai Co., Ltd.
  • 11. Eli Lilly and Company
  • 12. Exelixis, Inc.
  • 13. F. Hoffmann-La Roche AG
  • 14. Genmab A/S
  • 15. Gilead Sciences, Inc.
  • 16. GlaxoSmithKline plc
  • 17. Incyte Corporation
  • 18. Johnson & Johnson Services, Inc.
  • 19. Merck & Co., Inc.
  • 20. Merck KGaA
  • 21. Novartis AG
  • 22. Pfizer Inc.
  • 23. Regeneron Pharmaceuticals, Inc.
  • 24. Sanofi S.A.
  • 25. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. TARGETED THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. TARGETED THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL TARGETED THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES TARGETED THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES TARGETED THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. TARGETED THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. TARGETED THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. TARGETED THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL TARGETED THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. TARGETED THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE MEDICINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL TARGETED THERAPY MARKET SIZE, BY APOPTOSIS INDUCERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL TARGETED THERAPY MARKET SIZE, BY GENE EXPRESSION MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL TARGETED THERAPY MARKET SIZE, BY HORMONE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL TARGETED THERAPY MARKET SIZE, BY SIGNAL TRANSDUCTION INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL TARGETED THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL TARGETED THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL TARGETED THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL TARGETED THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL TARGETED THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL TARGETED THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL TARGETED THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL TARGETED THERAPY MARKET SIZE, BY RENAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES TARGETED THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 196. TARGETED THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 197. TARGETED THERAPY MARKET, FPNV POSITIONING MATRIX, 2023